ResearcherColumbia University Irving Medical CenterActive in the last 2 years

Maryam Safari

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4972-6780; OpenAlex author ID A5004048504. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2025.101312 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Susan Elaine Bates · 1 shared paper, 2026 · strength 0.23
- Paper Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2025.101312 ↗
Ravikanth Maddipati · 1 shared paper, 2026 · strength 0.23
- Paper Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2025.101312 ↗
Agnès Basseville · 1 shared paper, 2026 · strength 0.23
- Paper Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2025.101312 ↗
Kenneth P. Olive · 1 shared paper, 2026 · strength 0.23
- Paper Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2025.101312 ↗
Tito Fojo · 1 shared paper, 2026 · strength 0.23
- Paper Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2025.101312 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.